A better knowledge of the immunosuppressive role played by the tumor microenvironment has also been important to select a combination of immune checkpoint inhibitors (e.g., a combination of PD-1 or PD-L1 + CTLA4 inhibitors). This evidence concerns the gene CD274 and neoplasm.